ILMN
Illumina, Inc. Health Care Laboratory Analytical Instruments S&P 500Russell 3000
$235.99Close
$36.1BMarket cap
$99.01 – $293.6952-week range
Jan 28, 2027Next report · estimated
Highlights
Strengths
- Leading the market RS 95 · stronger than 95% of stocks over 12 months
- Volume drying up last 10 days 27% under the 50-day average
- Earnings growing EPS +47% year on year, faster than the quarter before (+56 pts)
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
down 12.4%
price change
1mo
down 13.8%
price change
12-month return
up 138%
market up 11% ·
its own up 137%
F-score
8 / 9
Exceptional
Altman Z
6.80
Low risk
P/E
42.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
13.3×
price / book
Earnings yield
up 2.2%
EBIT / enterprise value
Cheaper than
30%
of the market · expensive
Revenue growth
down 1%
year on year
EPS growth
up 47%
latest quarter · +56 pts
Sales growth
up 4%
latest quarter · -5 pts
ROE
up 33%
return on equity
Free cash margin
up 21%
$931.0M FCF
D/E
0.55
long-term debt / equity
Net debt / EBITDA
0.1×
Interest cover
—EBIT / interest
Piotroski tests
- took on more long-term debt
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Trade setup
ATR%
7.2%
$17.00 a day · 2×ATR $201.98
RS
95 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.8×
vs 50-day average
Up/down volume
0.82
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Revenue shrinking Revenue fell 0.7% over the year, from $4.4B to $4.3B.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026-16% vs market2 sessions after results
Options
$5.3M57.8% IV · activity
Financials
- Gross 66%
- Net 20%
- Free cash 21%
- Cash
- Long-term debt
| FY2020Jan 3, 2021 | FY2021Jan 2, 2022 | FY2022Jan 1, 2023 | FY2023Dec 31, 2023 | FY2024Dec 29, 2024 | FY2025Dec 28, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | $4.5B | $4.6B | $4.5B | $4.4B | $4.3B |
| Gross margin | 68% | 70% | 65% | 61% | 65% | 66% |
| Operating income | $580.0M | -$123.0M | -$4.2B | -$1.1B | -$833.0M | $807.0M |
| Net income | $656.0M | $762.0M | -$4.4B | -$1.2B | -$1.2B | $850.0M |
| Net margin | 20% | 17% | -96% | -26% | -28% | 20% |
| Earnings per share | $4.43 | $5.05 | -$28.05 | -$7.35 | -$7.69 | $5.45 |
| Free cash flow | $891.0M | $337.0M | $106.0M | $283.0M | $709.0M | $931.0M |
| Free cash margin | 28% | 7% | 2% | 6% | 16% | 21% |
| Cash | $1.8B | $1.2B | $2.0B | $1.0B | $1.1B | $1.4B |
| Long-term debt | $673.0M | $993.0M | $1.5B | $1.5B | $1.5B | $1.5B |
| Shareholders' equity | $4.7B | $10.7B | $6.6B | $5.7B | $2.4B | $2.7B |
| Shares outstanding | 146m | 157m | 158m | 159m | 159m | 153m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $209 – $264 ±11.6% by Nov 20, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Smaller 57.8% priced · 92.0% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $5.3M calls $2.1M · puts $3.3M · latest session
- 1.57× +1.03 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +265 · puts +454 past week
For options traders: ATM IV 57.8% (-10.5% 1w) · 1m ÷ 3m IV 1.07 · 25Δ skew -0.5 pts · Net GEX $325,613
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 27, 2026 | 33d |
| Jul 31, 2026 | Quarterly ↗ | Jun 28, 2026 | 33d |
| May 4, 2026 | Quarterly ↗ | Mar 29, 2026 | 36d |
| Feb 12, 2026 | Annual ↗ | Dec 28, 2025 | 46d |
| Oct 31, 2025 | Quarterly ↗ | Sep 28, 2025 | 33d |
| Aug 1, 2025 | Quarterly ↗ | Jun 29, 2025 | 33d |
| May 9, 2025 | Quarterly ↗ | Mar 30, 2025 | 40d |
| Feb 12, 2025 | Annual ↗ | Dec 29, 2024 | 45d |
| Nov 6, 2024 | Quarterly ↗ | Sep 29, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 16, 2024 | Annual ↗ | Dec 31, 2023 | 47d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Oct 13, 2026 | Material agreement · New obligation ↗ |
| Aug 17, 2026 | Other events ↗ |
| Aug 13, 2026 | Material agreement · Agreement ended · New obligation ↗ |
| Aug 12, 2026 | Other events ↗ |
| Aug 7, 2026 | Other events ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 23, 2026 | Director or officer change ↗ |
| May 26, 2026 | Shareholder vote ↗ |
| Apr 30, 2026 | Results · Other events ↗ |
| Apr 2, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 5, 2026 | Results ↗ |